A Phase 3 interventional study of somatropin and somatropin in Foetal Growth Problem and Small for Gestational Age, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2017-07-07.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is conducted in Japan. The aim of this trial is to assess the efficacy and safety of somatropin in children born small for gestational age (SGA) in Japan.
In the main period, subjects will receive either active treatment for 104 weeks (two dosing regimens) or no treatment for 52 weeks followed by an extension period where subjects who received active treatment for 104 weeks (two years) will continue with the same treatment for further 156 weeks (three years) while those subjects who received no treatment for 52 weeks (one year) will be randomised to receive two dosing regimens for 208 weeks (four years). In total, subjects participate in trial for 260 weeks (five years).
Main period is registered internally at Novo Nordisk as GHLIQUID-1516 while the extension period is registered as GHLIQUID-1517.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
Drug: somatropin
In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
Drug: somatropin
No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
Drug: somatropin
In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
Drug: somatropin
0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years
Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit
Time frame: Week 0, week 260
Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 208 - Subjects Received NN220 Treatment for 4 Years
Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit
Time frame: Week 0, week 208
Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 5 Years
Yearly Height velocity SDS for chronological age were summarised and graphically presented
Time frame: Weeks 0-260
Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 4 Years
Yearly Height velocity SDS for chronological age were summarised and graphically presented
Time frame: Weeks 0-208
Change in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years
Bone age is measured as years and months (displayed as xx.x years). Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....
Time frame: Week 0, week 260
Change in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years
Bone age is measured as years and months (displayed as xx.x years).Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....
Time frame: Week 0, week 208
Adverse Events - Subjects Received NN220 Treatment for 5 Years
Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly
Time frame: Weeks 0-260
Adverse Events - Subjects Received NN220 Treatment for 4 Years
Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly
Time frame: Weeks 0-208
44 sites in Japan
| Milestone | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|---|
| Started | 39 | 38 | 21 | 0 | 0 |
| Exposed to trial drug | 38 | 38 | 21 | 0 | 0 |
| Completed | 36 | 36 | 20 | 0 | 0 |
| Not completed | 3 | 2 | 1 | 0 | 0 |
| Milestone | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|---|
| Started | 33 | 33 | 0 | 10 | 10 |
| Completed | 23 | 27 | 0 | 7 | 5 |
| Not completed | 10 | 6 | 0 | 3 | 5 |
Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit
| Standard Deviation Score (SDS) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| Week 0 | -2.9488 ± 0.6368 | -2.9047 ± 0.6718 | — | — |
| Week 260 | 1.2066 ± 0.1102 | 2.0247 ± 0.1083 | — | — |
Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit
| Standard Deviation Score (SDS) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| Week 0 | — | — | -2.9603 ± 0.6689 | -2.7481 ± 0.3524 |
| Week 208 | — | — | 1.0997 ± 0.2453 | 1.9151 ± 0.2275 |
Yearly Height velocity SDS for chronological age were summarised and graphically presented
| Standard Deviation Score (SDS) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| Baseline, n=31, 34 | -1.6299 ± 0.9738 | -2.0303 ± 1.4527 | — | — |
| Week 52, n=29, 34 | 2.4717 ± 1.9848 | 4.7875 ± 1.9365 | — | — |
| Week 104, n=29, 32 | 1.1344 ± 1.2782 | 2.8877 ± 1.1272 | — | — |
| Week 156, n=25, 29 | 0.8015 ± 1.0583 | 2.1641 ± 1.5929 | — | — |
| Week 208, n=25, 28 | 0.3991 ± 1.3006 | 1.4724 ± 1.8696 | — | — |
| Week 260, n=23, 27 | 0.4612 ± 2.1558 | 0.7973 ± 2.1822 | — | — |
Yearly Height velocity SDS for chronological age were summarised and graphically presented
| Standard Deviation Score (SDS) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| Baseline, n=7,8 | — | — | 0.073 ± 1.5681 | -1.356 ± 0.708 |
| Week 52, n=7, 8 | — | — | 2.1677 ± 0.61 | 5.9303 ± 1.2096 |
| Week 104, n=6, 7 | — | — | 1.5268 ± 1.1715 | 3.3979 ± 1.0542 |
| Week 156, n=6, 7 | — | — | 1.7617 ± 2.0956 | 2.3539 ± 1.3149 |
| Week 208, n=6, 6 | — | — | 0.5475 ± 1.6055 | 2.199 ± 1.5973 |
Bone age is measured as years and months (displayed as xx.x years). Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....
| years | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| Change in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years | 5.79 ± 1.05 | 7.15 ± 1.05 | — | — |
Bone age is measured as years and months (displayed as xx.x years).Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....
| years | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| Change in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years | — | — | 6.54 ± 1.26 | 5.6 ± 1.68 |
Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly
| Subjects | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| AEs | 31 | 34 | — | — |
| AEs possibly/probably related | 9 | 16 | — | — |
| SAEs | 2 | 4 | — | — |
Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly
| Subjects | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment --> 0.033 mg | No Treatment --> 0.067 mg |
|---|---|---|---|---|
| AEs | — | — | 7 | 8 |
| AEs possibly/probably relate | — | — | 1 | 3 |
| SAEs | — | — | 0 | 1 |
Collected over The adverse events were collected from Aug 2004 to Dec 2009.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.033 mg / NN-220 | — | 12/31 (38.7%) | 31/31 (100%) |
| 0.067 mg / NN-220 | — | 11/34 (32.4%) | 34/34 (100%) |
| 0.033 mg / No Treatment | — | 1/7 (14.3%) | 7/7 (100%) |
| 0.067 mg / No Treatment | — | 2/8 (25%) | 8/8 (100%) |
| Event | 0.033 mg / NN-220 | 0.067 mg / NN-220 | 0.033 mg / No Treatment | 0.067 mg / No Treatment |
|---|---|---|---|---|
| Gastroenteritis viralInfections and infestations | 0/31 | 0/34 | 1/7 | 1/8 |
| Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders | 1/31 | 0/34 | 0/7 | 1/8 |
| ImpetigoInfections and infestations | 0/31 | 0/34 | 0/7 | 1/8 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 2/31 | 0/34 | 0/7 | 1/8 |
| ConvulsionNervous system disorders | 2/31 | 0/34 | 0/7 | 0/8 |
| Febrile convulsionNervous system disorders | 2/31 | 0/34 | 0/7 | 0/8 |
| PneumoniaInfections and infestations | 2/31 | 1/34 | 0/7 | 0/8 |
| StrabismusEye disorders | 2/31 | 1/34 | 0/7 | 0/8 |
| Meningitis asepticInfections and infestations | 0/31 | 2/34 | 0/7 | 0/8 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/31 | 1/34 | 0/7 | 0/8 |
| Event | 0.033 mg / NN-220 | 0.067 mg / NN-220 | 0.033 mg / No Treatment | 0.067 mg / No Treatment |
|---|---|---|---|---|
| InfluenzaInfections and infestations | 16/31 | 25/34 | 6/7 | 4/8 |
| NasopharyngitisInfections and infestations | 19/31 | 27/34 | 6/7 | 5/8 |
| BronchitisInfections and infestations | 14/31 | 15/34 | 0/7 | 6/8 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 22/31 | 22/34 | 5/7 | 6/8 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 8/31 | 8/34 | 1/7 | 5/8 |
| Gastroenteritis viralInfections and infestations | 11/31 | 9/34 | 0/7 | 4/8 |
| GastroenteritisInfections and infestations | 10/31 | 14/34 | 0/7 | 1/8 |
| PharyngitisInfections and infestations | 8/31 | 14/34 | 2/7 | 3/8 |
| ConjunctivitisEye disorders | 4/31 | 7/34 | 0/7 | 3/8 |
| Otitis mediaInfections and infestations | 7/31 | 12/34 | 1/7 | 3/8 |
| Age, Continuous(years) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| Mean | 5.46 ± 1.37 | 5.15 ± 1.2 | 5.09 ± 1.37 | 5.27 ± 1.3 |
| Sex: Female, Male(Participants) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| Female | 11 | 14 | 8 | 33 |
| Male | 24 | 20 | 7 | 51 |
| Ethnicity (NIH/OMB)(Participants) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 35 | 34 | 15 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 35 | 34 | 15 | 84 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| Japan | 35 | 34 | 15 | 84 |
| Height(cm) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| Mean | 96.19 ± 8.48 | 94.57 ± 7.28 | 94.42 ± 8.48 | 95.22 ± 7.96 |
| Body weight(kg) | 0.033 mg / NN-220 | 0.067 mg / NN-220 | No Treatment | Total |
|---|---|---|---|---|
| Mean | 13.31 ± 2.55 | 12.62 ± 1.81 | 12.47 ± 2.93 | 12.88 ± 2.36 |
Ran from Aug 2004 to primary completion in Mar 2006, 19 months.
Results were first posted in Jul 2011, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone